fig3

From: Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Integrating genomic mutations and tumor-infiltrating lymphocytes improves prediction of response to trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer

Figure 3. Association of TRAG signature status, CNA burden, and TIL levels with DFS in the training cohort. Kaplan-Meier estimates of DFS according to: (A) TRAG status (wild-type vs. mutant) (HR = 3.57; 95%CI: 1.58-8.02; P < 0.001); (B) CNA burden (low vs. high) (HR = 1.51; 95%CI: 0.88-2.59; P = 0.137); and (C) TIL level (low vs. high) (HR = 2.44; 95%CI: 1.34-4.45, P = 0.003). wt: Wild-type; mt: mutant; ns: not significant; HR: hazard ratio; DFS: disease-free survival; CI: confidence interval; CNA: copy number alteration; TILs: tumor-infiltrating lymphocytes; TRAG: trastuzumab response-associated gene; TRAG: We derived a 15-gene signature associated with trastuzumab response (FLG, MAP1A, ASPM, MEN1, PTEN, SMAD2, SCN7A, BRCA1, CTNNA1, FYN, HRNR, MRE11, RNF43, DCTN1, and PCLO).

fig3

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico